Dimot MA
Suite to streamline market access for life sciences companies, accelerating the launch of new healthcare products.
| Date | Investors | Amount | Round |
|---|---|---|---|
€50.0k | Angel | ||
| Total Funding | 000k | ||
Related Content
While at European level regulatory Agencies approve new medicines and medical devices, each European country then imposes its own complex and specific procedures for access the market. This results in an average 400-day delay before a product can be sold in each country, causing millions of euros in lost revenue and management costs for every single day of delayed access.
Dimot MA is the first digital system specifically designed to address this market access challenge, reducing time to market and streamlining management with its process orchestration and execution management technology.
Keywords: market access, life sciences, digital system, healthcare, evidence generation, health economics, outcomes reasearch, health technology assessment